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ABSTRACT
The glycerophospholipid phosphatidylcholine is the most abundant phospholipid 
species of eukaryotic membranes and essential for structural integrity and signaling 
function of cell membranes required for cancer cell growth. Inhibition of choline 
kinase alpha (CHKA), the first committed step to phosphatidylcholine synthesis, by 
the selective small-molecule ICL-CCIC-0019, potently suppressed growth of a panel of 
60 cancer cell lines with median GI50 of 1.12 μM and inhibited tumor xenograft growth 
in mice. ICL-CCIC-0019 decreased phosphocholine levels and the fraction of labeled 
choline in lipids, and induced G1 arrest, endoplasmic reticulum stress and apoptosis. 
Changes in phosphocholine cellular levels following treatment could be detected 
non-invasively in tumor xenografts by [18F]-fluoromethyl-[1,2–2H4]-choline positron 
emission tomography. Herein, we reveal a previously unappreciated effect of choline 
metabolism on mitochondria function. Comparative metabolomics demonstrated that 
phosphatidylcholine pathway inhibition leads to a metabolically stressed phenotype 
analogous to mitochondria toxin treatment but without reactive oxygen species 
activation. Drug treatment decreased mitochondria function with associated reduction 
of citrate synthase expression and AMPK activation. Glucose and acetate uptake were 
increased in an attempt to overcome the metabolic stress. This study indicates that 
choline pathway pharmacological inhibition critically affects the metabolic function of 
the cell beyond reduced synthesis of phospholipids.
INTRODUCTION
The majority of neoplasms share the characteristic 
of a deregulated cellular metabolism to satisfy the 
diverse demands of biomolecule synthesis required 
for proliferation [1, 2]. Elevated glucose utilization is 
clinically routinely assessed by 2-deoxy-2-18F-fluoro-D-
glucose  ([18F]-FDG) positron emission tomography (PET) 
imaging for cancer diagnosis and treatment surveillance. 
In addition to altered glycolytic handling, lipid metabolism 
is also frequently deregulated in cancer, particularly in 
metabolically challenging microenvironments with limited 
nutrient availability; under such conditions cancer cells 
activate de novo lipogenesis to support growth [3–5]. 
The synthesized fatty acids serve as membrane 
components important for the cell’s structural integrity and 
lipid signaling function.
The glycerophospholipid phosphatidylcholine 
(PC) is the most abundant phospholipid species of 
eukaryotic membranes and synthesized via the CDP-
choline pathway (Supplementary Figure S1A). Upon 
uptake, choline is phosphorylated via choline kinase 
(CHK) to phosphocholine (PCho). The high energy 
donor CDP-choline is then formed from the activating 
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nucleotide cytidine triphosphate (CTP) and PCho 
by CTP:phosphocholine cytidylyltransferase (CCT). 
In the final step, CDP-choline:1,2-diacylglycerol 
cholinephosphotransferase (CPT) catalyzes the formation 
of PC from CDP-choline and diacylglycerol (DAG). CHK 
exists in at least three isoforms: CHKA1, CHKA2 and 
CHKB encoded by two separate genes, of which the A, 
but not the B isoforms, have been implicated in cancer [6]. 
While under normal physiological conditions, CCT is the 
rate-limiting step of the pathway, CHKA is anticipated to 
be a major regulator in cancer [7, 8].
Aberrant choline metabolic profiles and concomitant 
CHKA upregulation have been described in most human 
malignancies, including lung, breast, prostate and 
endometrial cancer [9–13]. Use of the radiolabeled choline 
analogue [11C]-choline was recently approved by the US 
Food and Drug Administration as a diagnostic tool for 
staging of recurrent prostate cancer. Hyperactivated choline 
metabolism is characterized by elevated intracellular 
concentrations of PCho and total choline-containing 
metabolites [14]. The overexpression of CHKA, has been 
identified to be mainly responsible for this phenotype 
[7]. CHKA expression is of prognostic significance in 
clinical breast and lung cancer, where overexpression 
correlates with disease progression, poor prognosis and 
reduced survival [9, 15]. Additionally, CHKA has been 
linked to drug resistance by activating multidrug resistance 
transporters and to invasiveness [16, 17]. Breast cancer cells 
exhibit with increasing malignant progression correlatively 
elevated PCho accumulation [18].
The CDP-choline pathway is distinctly regulated by 
de novo fatty acid biosynthesis. Choline kinase activity is 
stimulated by growth factors, like epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF), as well 
as oncogenes including Ras, Raf, Mos and c-Src [7]. 
Although many mitogenic and growth promoting factors 
result in CHKA, but not CCT, activation, the exact 
mechanisms remain unclear. Transcriptional silencing of 
CHKA depletes the intracellular PCho pool [19, 20], which 
translates into reduced proliferation of MDA-MB-231, 
MDA-MB-468 and HeLa cells [20, 21] and induction of 
apoptosis [22]. Furthermore, it promotes differentiation, 
prevents anchorage-independent growth in HeLa cells 
and abolishes their ability to form xenografts in athymic 
mice [20, 21]. Due to its involvement in oncogenic 
transformation, upregulation in a variety of cancers, and 
interaction with key signal transduction pathways, CHKA 
has emerged as a potential target for cancer therapeutics. 
Previous pharmacological approaches lacked sufficient 
reporting of specificity, selectivity over other kinases, 
pharmacokinetics and pharmacodynamics. Furthermore, 
the effect of CHKA inhibition on metabolism beyond the 
CDP-choline pathway is unappreciated. Here we elucidate 
the impact of CHKA inhibition on tumor metabolism 
using the novel and specific inhibitor ICL-CCIC-0019.
RESULTS
ICL-CCIC-0019 is a potent and selective CHKA 
inhibitor
Using a focused-library screen, we recently identified 
a novel small-molecule CHKA inhibitor, ICL-CCIC-0019 
(Figure 1A) that is competitive with choline, but not ATP 
[23]; see this reference for full synthesis of ICL-CCIC-0019 
(compound 8 therein). In the present study, we show that 
the compound inhibits CHKA activity with an IC
50
 of 
0.27 ± 0.06 μM and compared with previously described 
easily accessible CHK inhibitors, is equipotent to MN58B 
and > 500 times more potent than CK37 (Figure 1B, 
Supplementary Figure S1B). The substantially less 
demanding synthesis of ICL-CCIC-0019 compared with 
MN58B bears additional advantages. ICL-CCIC-0019 dose-
dependently reduced the uptake of [3H]-choline into HCT116 
cells with an EC
50
 of 0.98 ± 0.24 μM (Figure 1C). This 
consequently diminished intracellular PCho concentration, 
and importantly, the incorporation of [3H]-choline into 
lipids (Figure 1D). Diminution of [3H]-choline labeling of 
lipids occurred at similar levels to PCho, suggesting that 
ICL- CCIC-0019 not only depleted the intracellular PCho 
pool, but also inhibits the synthesis of choline-containing 
lipids, like PC. To assess kinase specificity, ICL-CCIC-0019 
was tested against a panel of 131 human kinases (Figure 1E 
and Supplementary Table S1). The compound showed low 
off-target effects as only 5 kinases were inhibited more 
than 20% at a concentration of 10 μM (≤ 35% in all 131 
kinases). Inhibition greater than 20% was attained for 
insulin-like growth factor 1 (IGF-1R, 35 ± 7% inhibition), 
mitogen-activated protein kinase-activated protein kinase 
3 (MAPKAP-K3, 33 ± 6%), extracellular signal regulated 
kinase 8 (ERK8, 31 ± 4%), ribosomal S6 kinase 1 (RSK1, 
22 ± 6%), and v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (HER4, 21 ± 7%).
In an initial cell line screen comprising 8 cancer 
and 2 normal cell lines, cancer-derived lineages were 
preferentially inhibited with a mean half-maximal 
growth inhibitory concentration (GI
50
) of 1.09 μM (range 
0.38–2.7 μM), while normal cells were insensitive at 
these concentrations (GI
50
 30–120 μM; Figure 1F). The 
compound was then screened against a larger panel of 
cancer cell lines of diverse histopathologic origin, the 
NCI-60 screen [24]. The median GI
50
 across all cell lines 
was 1.12 μM (range 0.0389–16.2 μM, Figure 2). Breast 
and non-small lung cancer cell lines were most sensitive 
(median GI
50
 0.627 and 0.751 μM, respectively), which 
is line with evidence in the literature of particularly 
deregulated choline biochemistry in those cancers [9, 10]. 
Furthermore, the antiproliferative activity of ICL-
CCIC-0019 proved to be equipotent to MN58B and 
superior to CK37 (Supplementary Figure S1C). Mining 
of publicly available Cancer Genome Atlas (TCGA) 
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Figure 1:  ICL-CCIC-0019 is a selective and potent choline kinase inhibitor. (A) Structure of ICL-CCIC-0019. (B) Enzymatic 
inhibition of recombinant human Δ49N CHKA2 CHKA against ICL-CCIC-0019, MN58B and CK37. (C) [3H]Choline uptake in HCT116 
cells. Mean of n = 3 ± SD; **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. (D) Formation of [3H]PCho and incorporation of radioactive 
label into lipids. Mean of n = 6 ± SD; ****P ≤ 0.0001. (E) Kinase selectivity screen against 131 kinases. (F) Antiproliferative activity of 
ICL-CCIC-0019 against a panel of human cancer (black lines) and normal (grey) cell lines.
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expression data identified CHKA amplification and/or 
mRNA upregulation in 11% of breast, 5–10% of lung, 
8% of ovarian, 7% of colorectal and 5% of prostate 
cancers. Furthermore, CHKA mRNA expression is 
higher in multiple tumor types compared to normal tissue 
(Supplementary Figure S1D). The gene was rarely mutated 
or deleted (0–2.5% mutation rate and < 1% deletion among 
all tested cancer types). The consistently high expression 
in a wide variety of tumor types highlights the relevance 
of CHKA in malignancy and role as a therapeutic target. 
Knockdown of CHKA by shRNA produced 
similar biochemical and growth inhibitory effects as 
ICL-CCIC-0019 (Supplementary Figure S1E–S1H). 
Due the bolaamphiphilic character of the ICL-
CCIC-0019 compound class, comparable to surfactants, 
we investigated the potential of the compound to non-
specifically lyse cells. Surfactant-induced cell lysis 
triggers formation of pores in the cell membrane and 
subsequent release of cytosolic proteins, such as lactate 
dehydrogenase (LDH), into the supernatant [25]. 
Incubation of HCT116 cells with 1–25 μM ICL-
CCIC-0019 did not elevate LDH concentration in the 
supernatant (Supplementary Figure S1I). Furthermore, 
enzyme dimerization, which is required to exert CHKA 
activity, was not compromised by treatment with ICL-
CCIC-0019 (Supplementary Figure S1J), inferring that 
the mechanism of action did not involve destabilization of 
CHKA complexes.
Figure 2: Antiproliferative activity of ICL-CCIC-0019 against the NCI-60 panel of cell lines. Mean bar graph and GI
50
 
values of all tested cell lines. Bars depict the deviation of individual cell lines from the overall mean value for all the cells tested.
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CHKA inhibition arrests cell cycle and causes 
ER stress response
ICL-CCIC-0019 dose-dependently arrested cells 
in the G1 phase of the cell cycle after 24 h of treatment 
(2-fold increase at 10 μM) and increased the sub-G1 
population, representing apoptotic and dead cells, 3.7-
fold after 48 h (Figure 3A). Caspase-3/7-mediated 
apoptosis was seen following 48 h treatment with varying 
concentrations of ICL-CCIC-0019 in HCT116, HUH-7 
and MDA-MB-468 cells (Figure 3B). Depletion of PC 
was previously shown to induce ER stress [26]. Therefore, 
the expression of ER stress response markers was 
investigated. ICL-CCIC-0019 dose- and time-dependently 
increased the expression of ATF4, a transcription factor for 
target proteins that resolve ER stress, and to lesser extent 
IRE1α (Figure 3C). In keeping with above, expression and 
nuclear localization of the transcription factor CHOP was 
higher in ICL-CCIC-0019 treated cells independent of 
protein ubiquitination and HSP70 expression. Moderate 
increases in HSP90 expression might have further 
contributed to the ER stress phenotype. Notably, ER stress 
was not accompanied by formation of reactive oxygen 
species (ROS, Figure 3D). 
ICL-CCIC-0019 inhibits CHKA in vivo and has 
potent antitumor activity
We selected the HCT116 xenograft model 
for further work. HCT116 cells have intermediate 
sensitivity to ICL-CCIC-0019 and we have previously 
shown that the model is sensitive to inhibitory activity 
of other drugs on [18F]-D4-FCH tumor uptake [27]. 
Plasma pharmacokinetic profiles were established in 
BALB/c mice following a single injection of 10 mg/kg 
ICL-CCIC-0019. ICL-CCIC-0019 was rapidly cleared 
following i.p. administration and plasma concentrations 
above the GI
50
 of HCT116 cells were maintained for ca. 
50 minutes (Figure 4A). Analysis of plasma indicated that 
the compound was metabolically stable (Supplementary 
Figure S2A) although its oral bioavailability was 
limited. BALB/c nude mice bearing HCT116 xenografts 
were employed for analysis of tumor, liver, kidney and 
plasma concentrations (Figure 4B). The compound was 
rapidly extracted by the investigated tissues and tumor 
concentrations above the GI
50
 were maintained throughout 
the study (Figure 4B). Extensive accumulation in liver and 
kidneys were observed, although clearance from liver was 
more rapid than from tumor. In HCT116 xenograft bearing 
mice, treatment with ICL-CCIC-0019 on days 1–3 with 
5 mg/kg i.p. once a day followed by an 11 day recovery 
period (consistent with the inhibitor’s pharmacokinetics) 
resulted in potent antitumour activity (Figure 4C). To 
determine whether ICL-CCIC-0019 could attenuate 
CHKA activity in vivo, [18F]-D4-FCH PET imaging was 
performed. The radiotracer and inhibitor target the same 
protein, thus permitting non-invasive assessment of 
enzyme activity (pharmacodynamics) in the physiological 
and complex milieu of the tumor, as well as normal tissues. 
A marked reduction in radiotracer uptake was observed 
in ICL-CCIC-0019-treated HCT116 xenografts at 24 and 
48 hours following a i.p. single dose of 10 mg/kg, compared 
to the vehicle-treated cohort [AUC
0–60
 control: 191.9 
(%ID/mL)*min; AUC
0–60 
24 hours: 145.8 (%ID/mL)*min; 
AUC
0–60 
48 hours: 139.4 (%ID/mL)*min; Figure 4D–4E]. 
Interestingly, despite the rapid tissue distribution, whereby 
ICL-CCIC-0019 concentrations in the tumors peaked 
at 2 hours post injection, PET imaging at 6 hours post 
ICL-CCIC-0019 administration did not result in significant 
reduction of [18F]-D4-FCH uptake [AUC
0–60
 6 hours: 187.7 
(%ID/mL)*min]. While cardiac pharmacodynamics were 
not influenced by treatment, liver and kidney radiotracer 
retentions were diminished, comparable to tumor data 
(Figure 4F and Supplementary Figure S2B). 
We employed kinetic modeling to further 
characterize ICL-CCIC-0019-mediated choline kinase 
inhibition in vivo. Whereas normalized tissue uptake 
values reflect tracer concentration in a 3-dimensional 
region of interest, kinetic modeling accounts for tissue 
uptake relative to plasma. A two-tissue irreversible 
compartmental model, as previously reported, was 
employed with the hypothesis that k3 would represent 
the rate by which the tracer is phosphorylated by 
choline kinase [28], (Supplementary Figure S2C). 
Although this enzymatic reaction is in principle 
reversible, it was assumed that the high dependency 
of cancer cells to incorporate choline made it unlikely 
that catalytic hydrolysis of PCho prevails. Best fits and 
more physiological parameters were obtained with a 3k 
(excluding k4) instead of a 4k model. ICL-CCIC-0019 
treatment significantly decreased tumor K1, denoting the 
flux from blood to tissue, at all investigated time points 
(73% and 75% decrease compared to control after 24 and 
48 hours, respectively; Supplementary Figure S2D) and 
to a lesser extent in kidneys and liver (Supplementary 
Figure S2D). The opposing flux from tissue into the blood 
stream, k2, was slightly decreased by treatment in tumor 
(Supplementary Figure S2D). Interestingly, the micro 
rate constant k3, which represents intracellular radiotracer 
trapping, was non-significantly altered (Supplementary 
Figure S2D). In consequence to these micro parameter 
changes, the macro parameter Ki denoting the net 
irreversible uptake rate was significantly decreased in 
tumor after 48 hours (Figure 4G and Supplementary 
Figure S2D); changes in kinetic flux were predominantly 
driven by alterations in K1. In all examined tissues, the 
blood volume Vb decreased initially after treatment 
(Supplementary Figure S2D). These perfusion deficits 
were more pronounced and persistent in tumor compared 
to liver and kidney. To rule out that these kinetic changes 
are solely due to choline transport inhibition, we analyzed 
the choline metabolites of [18F]-D4-FCH in HCT116 cells 
Oncotarget6www.impactjournals.com/oncotarget
treated with ICL-CCIC-0019. As expected for CHKA 
inhibition, ICL-CCIC-0019 decreased the [18F]-D4-PCho 
peak, changing the relative ratio of [18F]-D4-Cho:[18F]-D4-
PCho from 72:28 in the vehicle control to 87:13 in the 
treatment group (Supplementary Figure S2E–S2F).
These data support that ICL-CCIC-0019 is a specific 
CHKA inhibitor, capable of inhibiting its target in vivo 
resulting in potent antitumor activity.
Effect of CHKA inhibition on soluble cellular 
metabolites
We then investigated the metabolic consequences 
of CHKA inhibition by ICL-CCIC-0019 using liquid 
chromatography-mass spectrometry (LC-MS) of soluble 
metabolites. CHKA inhibition expectedly decreased the 
uptake of choline from the media and potently depleted 
the intracellular PCho pool (−56% at 1 μM and −61% 
at 10 μM for 24 h, Figure 5A). Unexpectedly, given the 
reduction in 3H-choline incorporation into lipids (Figure 
1D), CDP-choline was dose-dependently higher after 
inhibitor treatment (Figure 5A). CDP-ethanolamine 
pathway intermediates (phosphoethanolamine and CDP-
ethanolamine), as well as precursors of diacylglycerol 
required for PC synthesis such as glycerol-3-phosphate and 
dihydroxyacetone phosphate (DHAP) were also increased 
following ICL-CCIC-0019 treatment (Figure 5B) 
suggesting inhibition or reduced substrate availability 
for processes culminating in PE and PC synthesis, 
independent of PCho inhibition. PCho is affected by 
phospholipid breakdown. In the HCT116 cell line, 
however, NMR-detectable glycerophosphocholine (GPC) 
levels were below the level of quantification (LoQ) 
relative to PCho; GPC levels were still undetectable 2 h 
after treatment with ICL-CCIC-0019 but increased at 24 h 
to levels just above the LoQ (data not shown) indicating 
the GPC pathway plays a minor role in this setting.
Treatment with ICL-CCIC-0019 markedly 
decreased citrate and cis-aconitate at 1 and 10 μM, and 
alpha-ketoglutarate at the high concentration (Figure 5B). 
Figure 3: ICL-CCIC-0019 induces G1 arrest, increases sub-G1 population and causes ER stress. (A) HCT116 cells 
were incubated with inhibitor for 24 or 48 hours and cell cycle populations quantified by flow cytometry using propidium iodine staining. 
(B) HCT116 cells were incubated with indicated doses in μM of ICL-CCIC-0019 for 48 hours and caspase 3/7 activity determined by 
caspase Glo assay and normalized to protein. Data are mean of n = 3 ± SD; ***P ≤ 0.001. (C) Analysis of key regulators of ER stress in 
HCT116 cells by western blot and immunofluorescence. Tunicamycin (2 μg/mL for 4 hours) was used as positive control. (D) Formation of 
reactive oxygen species in HCT116 cells upon ICL-CCIC-0019 treatment. CTR, control, NAC, N-acetyl cysteine, Data in A, B and D are 
expressed as mean of n = 3 ± SD; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Succinate and malate were unaffected (data not shown). 
This prompted us to examine in more detail the changes 
in metabolism to overcome the TCA cycle defect. The 
resulting energy crisis led to increases in the glycolytic 
intermediate fructose-1,6-bisphosphate (Figure 5B). 
Low AMP/ATP ratio allosterically stimulates glycolysis 
through the rate limiting enzyme phosphofructokinase. We 
observed an increased [18F]-FDG uptake (Supplementary 
Figure S3A) indicating enhanced glucose flux. Uniformly 
13C-labeled glucose flux studies confirmed increased 
glycolysis, as shown by increased glucose-6-phosphate and 
glyceraldehyde-3-phosphate (Supplementary Figure S3B), 
as well as diminished TCA cycle activity (Figure 5C). 
The pentose phosphate pathway intermediate ribose 
phosphate was increased upon ICL-CCIC-0019 
(Supplementary Figure S3C), however, pathways that 
branch off glycolysis, as for example serine synthesis 
pathway, did not show increased labeling with 13C-glucose 
and elevated unlabeled serine suggested enhanced 
utilization of exogenous serine (Supplementary Figure 
S3D). Serine can condense with palmitate to make 3-keto-
dihydrosphingosine, a precursor of de novo ceramide 
synthesis previously implicated as a marker of choline 
kinase inhibitor MN58B [29]. Furthermore, serine can be 
a carbon donor to S-adenosylmethionine (SAM) in two 
ways; either as a methyl donor via the tetrahydrofolate 
(THF) cycle during methionine salvage or as a carbon 
donor to the adenosyl moiety of SAM during nucleotide 
Figure 4: Plasma and tissue pharmacokinetics of ICL-CCIC-0019. (A) BALB/c mice were administered 10 mg/kg ICL-
CCIC-0019 p.o. or i.p. and plasma obtained 5, 15, 30, 60 minutes and 2, 4, 6 and 24 hours post injection. Figure insert displays first 
120 minutes only. Plasma pharmacokinetic variables are shown. (B) Tissue distribution of ICL-CCIC-0019. HCT116 xenograft bearing 
BALB/c nude mice were treated with 10 mg/kg ICL-CCIC-0019 and plasma, tumor, liver and kidney inhibitor concentrations determined 
at indicated time points. (C) Antitumor activity of ICL-CCIC-0019 and body weight changes in a HCT116 xenograft model. Arrows 
indicate time of dosing. (D) Representative PET image using the target-competitive probe [18F]-D4-FCH in ICL-CCIC-0019-treated 
HCT116 xenografts. (E) TACs of dynamic PET imaging scans. (F) Tumor, liver and kidney-associated radioactivity upon ICL-CCIC-0019 
treatment. (G) The pharmacokinetic macro rate constant for net irreversible uptake, Ki, was computed employing a two-tissue irreversible 
compartmental model. Data represent mean of n = 4–5 per group ± SEM; *P ≤ 0.05. 
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biosynthesis (via glycine and the THF cycle) [30]. The 
ICL-CCIC-0019 concentration-dependent uptake and 
intracellular buildup of serine was found to be associated 
with a 11% increase in SAM and 26% decrease in 
S-adenosylhomocysteine (SAH) perhaps suggesting an 
increase in phosphatidylethanolamine N-methyltransferase 
activity to supply PC from phosphatidylethanolamine 
(PE; rather than PE to phosphatidylserine using serine; 
thus serine buildup) under the nutrient stress associated 
with reduced PC synthesis. It is interesting to note that the 
rate of serine biosynthesis was comparable in vehicle and 
ICL-CCIC-0019 treated cells (Supplementary Figure S3E) 
while the biosynthesis of many other non-essential amino 
acids including aspartate and glutamate was strongly 
inhibited (Supplementary Figure S3F–S3G). This suggests 
that cells expedite serine biosynthesis for SAM production 
and downstream PC generation from PE or even ceramide 
production.
Furthermore, de novo fatty acid synthesis was 
inhibited and neither glucose nor acetate served as 
substrates, despite a 10-fold increased acetate uptake 
upon ICL-CCIC-0019 treatment (Figure 5D–5E). Most of 
the labeled acetate was incorporated into acetyl-carnitine 
(Supplementary Figure S3H). Of interest, medium chain 
carnitine esters and palmitoycarnitine were markedly 
increased (Supplementary Figure S3I) indicating an 
inability of the mitochondria to use medium chain esters 
derived from peroxisomes. Thus, the dysfunctional TCA 
cycle and consequent ER stress appear to increase glucose 
uptake, however, lack of possibilities to branch into other 
pathways result in almost quantitative secretion as lactate 
(Supplementary Figure S3J). The lack of glutamine uptake 
under these conditions (Supplementary Figure S3J) is in 
keeping with a dysfunctional TCA cycle/mitochondria. 
While palmitate M+2 from glucose was higher in drug 
treated samples, there was a stark reduction in other 
isotopologues (M+4, M+6, M+8, M+10, M+12, and 
M+14). Restoration of naturally occurring M+2 from 
palmitate when labeling ceases, or unperturbed elongase 
activity (mediating addition of glucose-labeled acetyl-
CoA unit to pre-existing myristate) could have led to the 
changes in palmitate M+2 seen.
Mitochondrial dysfunction and AMPK as 
downstream targets of choline kinase inhibition
A number of observations above led us to further 
examine a previously unappreciated involvement of 
mitochondria in the mechanism of action of choline 
kinase inhibition. Seahorse assays confirmed a dose-
related suppression of mitochondrial respiration at 
24 h after inhibitor treatment (Figure 6A, 6B). In the 
presence of glucose in medium, ICL-CCIC-0019 
decreased mitochondrial oxygen consumption (basal, 
ATP production, maximum respiration, spare capacity 
and proton leak) in a drug concentration related manner. 
Interestingly, ICL-CCIC-0019 and MN58B decreased 
mitochondrial respiration immediately after adding 
inhibitor (acute effect; Supplementary Figure S4A, S4B). 
The marked inhibition of TCA cycle without increased 
ROS, suggested a non-classical mitochondrial toxin effect. 
Against the background of energy stress we examined 
AMPK substrates. Both phospho-acetyl-CoA carboxylase 
(pACC) and AMPK pT172 increased with CHKA inhibitor 
treatment in a concentration dependent manner in support 
of AMPK activation (Figure 6C); total ACC was not 
sensitive to different drug concentrations (Supplementary 
Figure S4B). Cell-free kinase assays indicated that 
ICL-CCIC-0019 did not directly alter AMPK activity 
(Figure 1E), while the inhibitor increased the AMP/ATP 
ratio (Supplementary Figure S4C). Thus the observed 
effect is indirect, likely via sensing of energy stress [31]. 
We showed that the reduction in citrate following 
CHKA inhibition was associated with drug concentration 
related decrease in citrate synthase expression in HCT116 
cells at 24 h after treatment (Figure 6C). Citrate synthase 
(CS), the first rate-limiting enzyme in the TCA cycle is 
critical for mitochondrial respiration. Knockdown of 
the protein stimulates glycolysis [32] in keeping with 
the observations of increased glucose flux seen above. 
Reduction in the nuclear encoded CS expression is 
also a marker of mitophagy, the selective removal of 
mitochondria through autophagy (for review see [33]). 
Disruption of mitochondrial function such as treatment 
with electron transport chain inhibitors or depletion of 
mtDNA does not generally affect CS enzyme expression 
or activity, making it a useful semi-quantitative indicator 
of mitochondria mass in cells. To confirm specificity of 
CS expression in this context we verified the effect of 
CHKA inhibition in A549 human lung cancer cells and 
isogenic cells with depleted mtDNA (A549 Rho). In 
these cells ICL-CCIC-0019 diminished CS expression 
irrespective of mtDNA status in comparison with COX2 
(Figure 6D). Mitochondria are highly dynamic organelles 
that exist in networks. Fluorescence microscopy of 
mitochondria stained with anti-mitochondrial antibody 
distinctly showed disruption of mitochondrial networks 
in cells treated with ICL-CCIC-0019 (Figure 6E). 
Furthermore tetramethylrhodamine, ethyl ester (TMRE)-
detectable mitochondrial membrane potential decreased 
with ICL-CCIC-0019 or MN58B treatment (Figure 6F) 
compared to vehicle control or negative control (small 
molecule AMPK activator, 991 [34]). 
DISCUSSION
The glycerophospholipid PC is the most abundant 
phospholipid species of eukaryotic membranes and 
essential for structural integrity and signaling function 
of cell membranes required for cancer cell growth [35]. 
CHKA represents the first committed step to PC synthesis. 
The protein is overexpressed in several cancers through 
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amplification or mRNA upregulation. In cancer cells, 
overexpression of CHKA is associated with transformation 
of normal cells to cancer [18], and conversely, depletion 
of CHKA by RNAi can reduce cell survival and tumor 
growth (Supplementary Figure S1C and [8, 20, 36]). 
To date, attention in the field of cancer has focused on 
the requirement of choline together with channeling of 
fatty acids into PC synthesis to support the increased 
need for membrane synthesis; however, this mechanism 
alone does not explain the effects of chemical inhibitors. 
CHKA chemical inhibitors developed to date phenocopy 
CHKA knockdown showing a decrease in PCho levels, 
Figure 5: ICL-CCIC-0019 inhibits PC biosynthesis and increases glycolysis. Steady-state global metabolomics analysis of 
HCT116 cells treated with ICL-CCIC-0019 for 24 hours depicting CDP-choline and ethanolamine kinase pathway (A) and glycolysis, and 
TCA cycle intermediates (B). (C) HCT116 cells were treated with ICL-CCIC-0019 for 24 hours and subsequently subjected to 13C-labeled 
glucose for indicated times. Intracellular citrate is shown. (D) [3H]acetate uptake upon ICL-CCIC-0019 treatment in HCT116 cells. 
(E) 13C-glucose and 13C-acetate-derived isotopomer distributions of palmitate. Mean of n = 4 ± SD; *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001.
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however, only minimal cytotoxicity is seen with ATP-
site binding, relative to choline-site or mixed ATP-site/
choline-site inhibitors, leading to the suggestion that a 
CHKA-independent or non-catalytic role for CHKA is 
important for promoting cell survival [37]. We report the 
pharmacology of a new CHKA inhibitor, and demonstrate 
that CHKA chemical inhibition can induce profound ER 
stress response and inhibit mitochondrial respiration as 
additional potential mechanisms for reduced survival.
As a starting point, we focused on chemical 
inhibition of CHKA, using the selective choline-site 
specific CHK small-molecule ICL-CCIC-0019 [23]. 
Notably, structural similarities exist between the N,N-
dimethylaminopyridine moiety employed as a cationic 
Figure 6: Mitochondria dynamic changes upon CHK inhibition. Oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) of HCT116 cells following 24 h pre-treatment with ICL-CCIC-0019 (A), and following direct addition of ICL-CCIC-0019 (B). 
Vertical lines indicate the time of injection of ATP synthase inhibitor oligomycin (0.3 μg/mL), the pharmacological uncoupler FCCP (0.6 μM), 
complex III inhibitor antimycin (5 μg/mL), and complex I inhibitor rotenone (5 μg/mL) and ICL-CCIC-0019 (1 μM). (C) Effect of ICL-
CCIC-0019 on AMPK activation in HCT116 cells; phosphorylated acetyl-coA carboxylase (pACC), AMPK phosphorylation at Thr172 
(pT172), AMPK beta 1 and 2 subunits (B1 & B2) and citrate synthase (CS). (D) Effect of ICL-CCIC-0019 on citrate synthase in A459 
WT and isogenic A549 Rho cells. (E) Effect of ICL-CCIC-0019 (5 μM, 24 h) on mitochondrial networks. Cells were stained with anti-
mitochondrial antibody (green) and DAPI (blue). (F) Effect different inhibitors (10 μM each for 24 h) on mitochondria membrane potential 
measured by the tetramethylrhodamine ethyl ester dye method.
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choline-mimicking moiety in ICL-CCIC-0019 [23] and 
nature identical lipids such as C2/C6-ceramides, lyso-
phosphatidic acid and lyso-PC. ICL-CCIC-0019 was 
highly specific in a multi-kinase screen, decreased PCho 
levels together with the fraction of labeled choline in 
lipids (mainly PC), and induced G1 arrest, endoplasmic 
reticulum stress and apoptosis. We measured incorporation 
of [3H]-choline into lipids and assumed therefore that the 
diminution of the lipid labeled fraction is due to reduction 
of phosphatidylcholine. It should be noted, however, 
that [3H]-choline can be metabolized and incorporated 
into other lipids including phosphatidylethanolamine or 
phosphatidylserine, although these alternative mechanisms 
are likely to be limited compared to phosphatidylcholine. 
Phosphoethanolamine levels were not decreased upon 
drug treatment, suggesting that ICL-CCIC-0019 did not 
inhibit ethanolamine kinase. Reduction in cell survival 
occurred across 60 cell lines of diverse origin with median 
GI
50
 of 1.12 μM and the compound also inhibited colon 
cancer growth in mice. 
Based on our data, we assert that the ability of 
ICL-CCIC-0019 to effect rapid and sustained reductions 
of CDP-choline pathway, precluding significant cellular 
adaptation to replenish phosphatidylcholine, likely leads 
to reduction in proliferation seen across several cancer 
cell lines including the NCI-60 panel. It should be noted, 
however, that using a novel CHKA inhibitor, V-11–0711 
[37], two independent laboratories have shown that drug-
induced reductions of steady state PCho occurring after 
24 h in HeLa and MDA-MB-231 were not sufficient 
to decrease cell viability, compared to CHKA RNAi 
[37, 38]; cell viability was lost only in SUM149 cells 
at similar drug concentrations. The groups infer that it 
is the depletion of CHKA protein - acting through non-
catalytic functions [39] - but not inhibition of CHKA 
catalytic activity that is able to decrease cell survival. This 
conclusion, supported by the insensitivity of catalytically-
inactive mutant CHKA2 D306A transformed cells to 
EGF-stimulated growth [39], contrasts the substantial 
literature demonstrating anti-proliferative effect of 
diverse small molecule CHKA ATP-, choline- and mixed-
site binders on cell viability under unrestricted-growth 
media conditions and in mice [29, 40–44]. The hypothesis 
neither incorporates drug resistance possibilities, nor 
importantly the ability of the compounds to rapidly deplete 
phosphatidylcholine without significant regeneration. 
Thus, while non-catalytic (‘scaffold’) functions of 
CHKA exist [39], and loss of the PCho generation step 
alone may be insufficient to decrease cell viability under 
certain conditions, we cannot rule out that small molecule 
inhibitors can affect cell viability via the CDP-choline 
pathway due to rapid depletion of dynamic membrane 
phosphatidylcholine synthesis required for cellular 
integrity and mitochondria function.
Impaired choline transport and phosphorylation 
following treatment was detected non-invasively in 
tumor and liver by whole body [18F]-D4-FCH. The time-
dependent reduction in flux constant Ki of [
18F]-D4-FCH 
occurred as a result of drug accumulation in tissue and 
inhibition of CHK, and was associated with the tumor 
growth inhibition observed. The rapid uptake of labeled 
choline tracers, together with limited efflux back into the 
blood pool renders kinetic models unable to independently 
distinguish between K1 and k3; the macro-parameter Ki 
better reflects retention than k3 [28, 45]. Both K1 and Ki 
decreased with treatment suggesting that ICL-CCIC-0019 
inhibits choline extraction (transfer from blood to tissue) 
and retention. Indeed in vitro studies showed that ICL-
CCIC-0019 competes with a labeled choline tracer for 
uptake (Supplementary Figure S2E–S2F). At this stage, 
we notionally attributed the reduction in PC seen in 
vitro to reduction in PCho. We investigated whether a 
non-catalytic modulation of CHKA may be responsible 
for the reduced cell survival seen. Alteration in CHKA 
dimerization was unaffected by ICL-CCIC-0019 thus 
destabilization of the protein was ruled out. Induction of 
endoplasmic reticulum stress also led us to investigate 
ROS formation; ROS formation was ruled out as a 
mechanism of action.
We then resorted to metabolomics to identify 
additional mechanisms. We confirmed the reduction 
in PCho production and concomitant increases in free 
intracellular choline. CDP-Cho pool-size increased dose-
dependently with drug treatment indicating blockade 
of CPT. This observation was unexpected, and while 
consistent with our finding of reduced labeled choline 
incorporation into PC, could also be explained by 
activation of CCT. Further work is required to clarify the 
specific enzymes inhibited. The reduction in PC could 
also have resulted from reductions in fatty acids or DAG. 
In our studies we observed specific decreases in the 
following fatty acids: palmitoleic, oleic and dodecanoic 
acids, which could have contributed to the reduction in PC 
synthesis. DAG levels were not measured. Interestingly, 
the analogous CDP-ethanolamine:1,2-diacylglycerol 
ethanolaminephosphotransferase (EPT) was also inhibited 
but only at higher drug concentration. Very few inhibitors 
of CPT/EPT have been reported, and indeed, these two 
enzymes were not included in our selectivity screen. In 
their study, Bladergroen and co-workers noted that C2-
ceramides selectively inhibited CPT while C
6
-ceramides 
rapidly inhibited both CPT and EPT [46]. It is therefore 
more accurate to refer to ICL-CCIC-0019 as CDP-choline 
pathway inhibitor rather than a CHKA inhibitor as it 
inhibits the pathway at the commitment step and last step. 
Further to the effect on substrate incorporation into 
PC, we also revealed a previously unappreciated effect 
of chemically inhibiting CDP-choline pathway activity 
on mitochondria function. Comparative metabolomics 
demonstrated that CHKA inhibition leads to a metabolically 
stressed phenotype analogous to mitochondria toxin 
treatment at 24 h after ICL-CCIC-0019 treatment. 
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This drug-induced phenotype involved profound block of 
the TCA cycle characterized by a large decrease in steady 
state levels of mitochondria enzyme-related metabolites 
including citrate and cis-aconitate, whereas α-ketoglutarate 
only decreased at the higher concentration. Conversely, 
glycolysis was increased after short-term incubation with 
ICL-CCIC-0019 (increased ECAR) accompanied by 
elevation of glycolysis-related metabolic intermediates 
including fructose-1,6-bisphosphate, glucose-6-phosphate, 
dihydroxyacetone phosphate and serine to provide 
important substrates to overcome the TCA cycle block. 
Tracing studies using 13C-glucose and [18F]-FDG further 
confirmed the increased glycolysis in the context of higher 
glucose uptake and quantitative lactate secretion, together 
with increases in glycolytic intermediates (increases 
in glucose-6-phosphate, glyceraldehyde-3-phosphate, 
serine), and TCA block (decreased flux into citrate and 
decreased glutamine uptake). A study evaluating the 
metabolite profile of cells undergoing etoposide-induced 
apoptosis [47] reported increases in glucose-6-phosphate, 
glyceraldehyde-3-phosphate and fructose 1,6 bisphosphate 
with apoptosis; whether our findings are linked to 
apoptosis requires further work. In general, fluxes into 
long-chain saturated fatty acids increased after treatment, 
while long-chain unsaturated fatty acids decreased; 
concomitantly, mitochondrial fatty acid-β-oxidation 
appeared blocked. We envisaged that TCA cycle block 
would limit synthesis of fatty acid from glucose carbons 
while fatty acid synthesis from acetate may be unaffected. 
By tracing [14C]-acetate, we showed that acetate uptake 
was increased in a dose dependent manner. ACC1 and 
FASN are cytoplasmic enzymes that can convert acetyl-
coA to malonyl-coA and further to fatty acids; ACC2, 
which can also catalyse conversion of acetyl-coA to 
malonyl-coA, is a mitochondrial enzyme. The increased 
[14C]-acetate may be a survival mechanism. 
We show in this study that ICL-CCIC-0019 
inhibits mitochondrial function and activates glycolysis. 
The two processes may be linked. Intracellular citrate 
concentrations (decreased by ICL-CCIC-0019) and ATP/
AMP concentrations (determinants of AMPK activity) 
are potent modulators of the rate limiting glycolytic 
enzyme phosphofructokinase [48]. ICL-CCIC-0019 
activated AMPK (measured as increased pACC and pT172 
expression), which may have contributed to the activation 
of glycolysis. From the kinase screen, we know that the 
effect of ICL-CCIC-0019 on AMPK was not a direct 
one but rather via modulation of cellular (mitochondrial) 
dynamics and possibly downstream of changes in 
mitochondria membrane potential and profound reduction 
of mitochondria respiration. The decrease in mitochondrial 
respiration occurred rapidly, as early as 5 min after adding 
ICL-CCIC-0019 suggesting a possible direct interaction 
of drug with mitochondria. From the observations made 
in this study, other potential mechanisms that can generate 
the reduced mitochondrial respiration phenotype include 
enhanced ethanolamine pathway activity (increased 
PEth and CDP-Eth) [49] or reduction in PCho and PC/
PE [50, 51] and its effect on mitochondrial membrane 
asymmetry and membrane potential. Mitochondria have 
a strict requirement for highly dynamic translocation of 
membrane lipids synthesized in the cytoplasm, golgi or 
endoplasmic reticulum to support membrane integrity [52]. 
Changes in mitochondrial membrane potential in the 
hindlimb muscle of chkb-/- mice can be rescued by 
injection of CDP-choline suggesting a genetic basis 
in appropriate model systems. Thus, we can surmise 
that glycolysis was activated to support the inability of 
mitochondria to synthesize ATP (mitochondria membrane 
potential is required for ATP synthesis) and may explain 
the overall lack of significant reduction in cellular ATP.
Another interesting phenotype observed following 
treatment with ICL-CCIC-0019 was loss of mitochondrial 
networks. This was concomitant with a decrease of 
mitochondrial mass, characterized by reductions in citrate 
synthase expression in the colon cancer cells. Citrate 
synthase is a mitochondrial DNA encoded gene product, 
whose expression is a marker of cellular mitochondrial 
content (mitophagy biomarker). Interestingly, the ICL-
CCIC-0019-induced citrate synthase depletion occurred 
in both A549 wild-type and A549 Rho cells that had lost 
mtDNA indicating that the ‘mitochondria stress phenotype’ 
was not due to effects on mitochondria redox carriers 
(Complex I-IV) required for mitochondrial respiration. 
This was further supported by reduced aspartate levels 
(Supplementary Figure S3E), which is largely synthesized 
via mitochondrial glutamic-oxaloacetic transaminase 
(GOT2) [53]. There is evidence that AMPK - a sensor of 
energetics - couples nutrient sensing and environmental 
stress to mitophagy and cell survival via phosphorylation 
of ULK1/2 or hATG1 [54]. 
In summary, we report a new mechanism of 
action for CDP-choline pathway chemical inhibition 
by ICL-CCIC-0019. In this model, drug treatment 
elicits loss of mitochondria membrane potential and 
mitochondrial respiration. The mitochondrial stress 
that ensues is concomitant with increased glycolysis, 
a process that is associated with AMPK activation. 
These newly described properties of choline kinase 
chemical inhibitors need to be considered when rational 
combinations are proposed.
MATERIALS AND METHODS
Chemistry and radiochemistry
The syntheses of choline kinase inhibitors and [18F]-
D4-FCH have recently been reported [23, 28, 55].
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Cell culture and transfections
A431, A549, Ishikawa, MCF-7, and MDA-MB-468 
cells were maintained in DMEM (Sigma-Aldrich). A2780 
and HCT116 were maintained in RPMI (Sigma-Aldrich). 
St-T1b cells and MCF-10A cells were maintained in 
DMEM/F12 (Life Technologies). Media was supplemented 
with 10% FBS (Lonza) and antibiotics (Life Technologies). 
Cells were cultured at 37°C in humidified atmosphere 
containing 5% CO2. Cell lines were authenticated by 
provider by short-tandem repeat analysis. No additional 
authentication of cells was done by the authors. CHKA 
expression was silenced by doxycycline-inducible 
shRNAs targeting CHKA (pTRIPZ CHKA shRNA clones 
V3THS_335370 and V3THS_335372; Dharmacon) or 
non-targeting control (Dharmacon). Viruses were packaged 
using Trans-Lentiviral shRNA Packaging System (Open 
Biosystems). Knockdown was induced by incubation with 
0.5 μg/mL doxycycline for 5 days.
Choline kinase activity, proliferation, apoptosis 
and reactive oxygen species (ROS) assays
Enzymatic kinase activity, [3H]choline to [3H]PCho 
conversion and growth inhibition assays was conducted 
as previously described [23]. [3H]choline incorporation 
into soluble and lipid fractions was determined by a 
pulse-chase experiment. HCT116 cells were seeded at a 
density of 3 × 105 cell per well into 12-well plates and 
incubated overnight. Cells were treated with 1 or 10 
μM ICL-CCIC-0019 for 1 h and pulsed in presence of 
inhibitor with 18.5 kBq/mL [3H]choline chloride in 500 
μL for 1 additional h. Cells were briefly rinsed with RPMI 
and incubated with fresh, non-radioactive medium for 
6 h. Metabolites were extracted as described elsewhere 
[23], but additionally the radioactivity of the choline-
containing and chloroform (lipid-containing) fractions was 
measured. Uptake of radiolabeled metabolite-tracers was 
measured as described elsewhere [56]. Antiproliferative 
activity was measured after 72 h continuous exposure to 
inhibitors by sulforhodamine B (SRB) assay as described 
elsewhere [23]. Apoptosis was determined using Caspase 
3/7 Glo assay (Promega) according to the manufacturer’s 
instructions. 
For ROS measurements, cells were seeded in 96-
well plates and treated with indicated ICL-CCIC-0019 
(10 μM), pro- and antioxidants (0.25% H2O2 and 5 mM 
N-acetyl cysteine, NAC; all from Sigma-Aldrich) for 
indicated times. C400 (Life Technologies) was added at 
a final concentration of 50 μM and incubated at 37°C for 
15 minutes and fluorescence quantified.
Western blotting (general)
Cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer containing protease and phosphatase 
inhibitors (all from Sigma-Aldrich). Equal amounts of 
protein (20 μg) were resolved on 4–15% mini-protean 
TGX gels (Biorad) and transferred to PVDF membranes 
(Trans-Blot Turbo Transfer Packs, Biorad). Membranes 
were blocked for 1 h in 5% milk in Tris-buffered saline or 
phosphate buffered saline containing 0.1% v/v tween-20 
(TBST or PBST) and incubated with the following 
antibodies overnight at 4°C: Actin (Abcam, Cat. Nr.: 
ab6276), ATF4 (Cell Signaling, 11815), CHKA (Sigma-
Aldrich, HPA024153),  HSP70 (Cell Signaling, 4876), 
HSP90 (Santa Cruz Biotechnology, sc-69703), IRE1a 
(Cell Signaling, 3294), and Ubiquitin (Cell Signaling, 
3936). Secondary HRP-conjugated mouse and rabbit 
antibodies (Santa Cruz Biotechnology, sc-2004 and 
sc-2005, respectively) were applied for 1 h at room 
temperature. Signals were visualized using Amersham 
ECL Western Blotting Detection Reagent (GE Healthcare) 
and Amersham Hyperfilm (GE Healthcare).
Native gels were run using blue native 
polyacrylamide gel electrophoresis (BN-PAGE) 
method [57]. Cell homogenates were obtained by addition 
of passive lysis buffer (Promega) containing protease and 
phosphatase inhibitors to cell pellets and incubation for 30 
minutes on a tube rotor at 4°C. Samples were cleared by 
centrifugation for 10 minutes at 12 000 × g at 4°C. Samples 
were prepared by mixing 30 μg protein with an equal 
volume of 2 × sample buffer (62.5 mM Tris-HCl, pH 6.8, 
25% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 0.02% 
(w/v) Coomassi Blue G250; all from Sigma-Aldrich). As 
control, D49N CHKA2 [58] was either applied under 
native conditions (100 ng diluted to 10 μL in 100 mM 
Tris buffer pH 7.4 added to 10 μL 2 × sample buffer) 
or denatured using SDS [100 ng diluted in RIPA buffer, 
1 × NuPAGE LDS sample buffer and 1 × sample reducing 
agent (both Life Technologies)] and incubated at 70°C 
for 10 minutes. Samples were resolved on 4–15% mini-
protean TGX gels using 1 × native running buffer (25 mM 
Tris, 192 mM glycine, pH 8.3). The cathode buffer was 
additionally supplemented with 750 μL Coomassi Blue 
G250 [final concentration ca. 0.04% (w/v)]. Membranes 
were transferred and probed as described above.
DNA cell cycle analysis
Supernatant and cells were harvested, washed and 
centrifuged. The cell pellet was resuspended it 1 mL ice-
cold PBS and the suspension added to 9 mL 70% ethanol, 
while mixing gently. Cells were fixed for at least 2 hours 
at –20°C. Cells were centrifuged and rehydrated in 3 mL 
cold PBS for 15 minutes. Samples were stained in 500 μL 
buffer containing 100 mM Tris pH 7.4, 150 mM NaCl, 
1 mM CaCl2, 0.5 mM MgCl2, 0.1% Triton  X-100, 0.1 mg/ml 
RNase A, 50 μg/ml propidium iodide (all items from 
Sigma-Aldrich) at 37°C for 3 h protected from light. Data 
were acquired on a BD FACS Canto flow cytometer (BD 
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Bioscience) and analyzed using FlowJo 7.6.4 software 
(Tree Star).
Cell membrane integrity assay
Cell membrane integrity was assessed using a 
fluorescent kit measuring lactate dehydrogenase (LDH) 
release (CytoTox-ONETM, Promega) according to 
manufacturer’s instructions.
Immunofluorescence microscopy
HCT116 cells (3 × 104) were seeded into 4-well 
chamber slides (BD Biosciences), cultured overnight 
and treated with 1 or 10 μM ICL-CCIC-0019 for 24 h 
or 2 μg/mL tunicamycin (Sigma-Aldrich) for 4 h. 
Cells were washed 2 × 5 minutes with PBS and fixed 
with 4% formaldehyde (Sigma-Aldrich) in PBS for 
15 minutes at room temperature. Cells were washed 
3 × 5 minutes with PBS and permeabilized with 100 μL 
0.1% Triton X-100 in PBS for 10 minutes at room 
temperature. Cells were washed 3 × 5 minutes with PBS 
at room temperature and blocked with 1% BSA / 0.1% 
Triton in PBS (PBST-BSA) for 1 h at room temperature. 
Cells were incubated with CHOP primary antibody (Cell 
Siganling, 2895) at a dilution of 1:3000 in 100 μL/well 
PBST- BSA overnight at 4°C. The next day, cells were 
washed 3 × 10 min PBS and incubated with secondary 
Alexa fluor 594 goat anti-mouse IgG antibody (Life 
Technologies, Cat. Nr: A-21125) at a dilution of 1:400 
in 100 μL PBST-BSA for 1 h at room temperature in the 
dark. Cells were washed 3 × 10 minutes with PBS actin 
fibers stained with Phallloidin Alexa Fluor 488 (Life 
Technologies, Cat. Nr: A12379) for 15 min at room 
temperature. Cells were washed 3 × 10 minutes with PBS 
and coverslips mounted using ProLong Gold Antifade 
Reagent containing DAPI (Invitrogen, Cat. Nr: P-36931). 
Images were acquired on an Olympus BX51 microscope 
and DP controller software version 2.1.
Choline extraction and radio-HPLC
We determined the effect of ICL-CCIC-0019 on 
initial choline extraction (transport and phosphorylation; 
Supplementary Figure S2E–S2F) using a modification of 
previously described methods [59]. Instead of [14C]choline, 
we used the  catabolically more stable choline analogue, 
[18F]-D4-FCH. MN58b and Hemicholinium-3 (HC-3) were 
used as controls. HPLC was performed using methods 
previously reported by us for this  radiotracer [27].
Metabolomics
Unlabeled metabolite analyses were conducted as 
previously reported [5]. HCT116 cells cultured overnight 
in 6-well plates were treated with vehicle, 1 or 10 μM 
ICL-CCIC-0019 for 24 h prior to extraction. For flux 
experiments, HCT116 cells were plated onto 6-well plates 
and cultured overnight. The cells were then grown in 
medium containing vehicle or 1 μM ICL-CCIC-0019 for 
24 h. The medium was then replaced with that containing 
13C metabolites (5 mM 13C
6
-glucose or 0.2 mM 13C2-
acetate) and inhibitor for various indicated time points. 
Metabolites were extracted with a cold solution (−20oC) 
composed of methanol, acetonitrile, and water (5:3:2). 
The insoluble material was immediately pelleted in a 
cooled (0oC) centrifuge at 16,000 × g for 15 min and the 
supernatant was collected for subsequent LC-MS analysis. 
A ZIC-pHILIC column (4.6 mm × 150 mm, guard column 
2.1 mm × 20 mm, Merck) was used for LC separation 
using formic acid, water, and acetonitrile as component 
of the mobile phase. Metabolites were detected using an 
Exactive mass spectrometer (ThermoFisher).
Analysis of mitochondrial function 
Mitochondrial respiration
Extracellular acidification and oxygen consumption 
rates (ECAR and OCR) were measured in a XF24 
extracellular flux analyzer (Seahorse XF24 Extra Cellular 
Flux Analyzer, North Billerica, MA, USA). Basic XF 
assay medium was prepared as previously described [60] 
supplemented with glucose, and the pH adjusted to 7.4 at 
37°C. Indicated final concentrations of compounds were 
obtained by injecting appropriate amounts of compounds 
dissolved in DMSO or water and diluted in XF assay 
medium into ports. For ECAR and OCR measurements 
40–50,000 HCT116 cells were plated in each well in 
RPMI overnight and the assay was carried out according 
to the XF24 assay protocol suggested by the manufacturer. 
Indicated data points were obtained after 3 min mixing 
and 2 min wait, followed by 3 min of data collection. Data 
were normalized to the basal values.
Mitochondrial protein and phospho-protein expression
1.5–2.0 × 106 HCT116 cells were plated on 10 cm 
plates in RPMI medium. After 24 h, cells were treated 
with indicated concentrations of CHK inhibitors for a 
further 24 h. Plates were then washed with ice cold PBS 
and cells were removed with 300 μL lysis buffer (50 mM 
HEPES, 150 mM NaCl, 1 mM EDTA, 0.2 mM DTT, 1% 
triton and phosphatase and protease inhibitors), syringed 
through a 25G needle and incubated on ice for 10 min. 
Cell lysates were centrifuged at 14000 rpm for 30 min 
and the total extracts were collected and stored at –80°C. 
About 60 mg of cell extracts were used for western blot 
analysis. Antibodies used for western analysis include, 
from Millipore, total acetyl-CoA carboxylase (ACC; 
05-1098); from Cell Signalling, phosphorylated-ACC 
(pACC-S76; CS3661L), AMPK anti-pT172 (CS2535L), 
AMPK anti-B1 and B2 (CS 4150); from Abcam anti-
cytochrome C oxidase subunit II (MTCOX-2; ab110258), 
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anti-citrate synthase (CS; ab96600) and; from Santa Cruz 
Biotech, anti-GAPDH (FL-335). Antibody dilutions used 
were as suggested by the supplier.
Mitochondrial immunofluorescence
20,000 HCT116 cells were plated on glass 
coverslips. After 24 h, cells were treated with 5 μM 
ICL-CCIC-0019. After 24 h cells were fixed with 1% 
paraformaldehyde for 20 min and blocked with fish 
gelatin overnight. Blocked cells were incubated with 
antimitochondrial antibody (Abcam; ab110413, 1:200 
dilution) for 8–10 h. Coverslips were further washed 
with PBS and mounted with vector shield and DAPI, and 
imaged on a SP5 confocal microscope (Leica).
TMRE-Membrane potential assay
HCT116 cells were cultured as above with indicated 
inhibitors and subject to the tetramethylrhodamine ethyl 
ester dye method (TMRE) membrane potential assay 
according to the manufacturers instruction (Abcam 
ab113852) prior to FACS analysis.
Animal models
All animal experiments were conducted in 
accordance with the United Kingdom Home Office 
Guidance on the Operation of The Animals (Scientific 
Procedures) Act 1986 Amendment Regulations 2012 
and within the published guidelines for the welfare and 
use of animals in cancer research [61]. Xenografts were 
established in female BALB/c nude mice aged 6–8 weeks 
(Harlan) by subcutaneous (s.c.) injection of 100 μL 
HCT116 cells (5 × 106 in PBS) on the back of mice. 
Tumor dimensions were frequently measured by calliper 
and volumes calculated by the following equation: volume 
(mm3) = (π/6) × a × b × c, where a, b, and c represent 
3 orthogonal axes of the tumor. When tumor volumes 
reached approximately 50–100 mm3 (ca. 10 days post 
injection), mice were used for subsequent studies.
Pharmacokinetic and plasma metabolite studies
Plasma pharmacokinetic parameters of ICL-
CCIC-0019 were established in female BALB/c mice 
aged 6–8 weeks (Harlan). Mice were intraperitoneally 
(i.p.) or perorally (p.o.) administered a single dose of 
10 mg/kg and blood collected by cardiac puncture after 
5, 15, 30 minutes and 1, 2, 4, 6 and 24 h. For tissue 
pharmacokinetic studies, HCT116 xenograft bearing 
mice were administered 10 mg/kg ICL-CCIC-0019 
i.p. and blood collected after 5 minutes, 2, 6 and 24 h. 
Plasma was obtained by centrifugation at 1000 × g 
for 10 minutes. Samples were snap-frozen and stored 
at –80°C prior to analysis. Analysis was carried 
out by Cyprotex Inc. using liquid chromatography–
mass spectrometry (LC–MS). For analysis of plasma 
metabolites, 2-hour samples of tissue pharmacokinetic 
studies were pooled.
PET-CT imaging 
Mice were anesthetized through isoflurane 
inhalation and scanned on a Siemens Multimodality 
Inveon small animal PET-CT scanner for [18F]-D4-FCH 
PET studies using HCT116 xenografts. Low dose CT 
scans were first acquired (80 kVp, 0.5 mA, 220 degree 
rotation, 600 ms per degree exposure time, 80 μm 
reconstruction pixel size) for PET attenuation correction 
and anatomical reference. PET images were acquired 
following a bolus i.v. injection of approximately 3.7 
MBq tracer in the tail vein. Dynamic emission scans were 
acquired in list mode format over 60 minutes. Data were 
sorted into 0.5 mm sinogram bins and 19 time frames for 
image reconstruction by filtered back projection (4 × 15 
seconds, 4 × 60 seconds and 11 × 300 seconds). The 
Siemens Inveon Research Workplace software was used for 
visualization of radiotracer uptake. To define 3-dimensional 
regions of interest (ROI), 30 to 60-minute cumulative 
images of the dynamic were employed. Arterial input 
function was estimated by drawing ROIs over the center 
of the heart cavity using cumulative images from 0.25 
to 2 minutes of the dynamic series, a method previously 
validated for use in rodents [62]. The count densities were 
averaged for all ROIs at each time point to obtain time 
versus radioactivity curves (TAC). Tumor TACs were 
normalized to injected dose measured by a VDC-304 dose 
calibrator (Veenstra Instruments) and normalized uptake 
was expressed as percentage injected dose per mL tissue 
(NUV; %ID/mL).
Kinetic modeling of [18F]-D4-FCH data
Kinetic analysis of PET data was performed 
applying a standard two-tissue irreversible compartmental 
model described in detail elsewhere [28].
TCGA data analysis
The results shown here are in whole based upon 
data generated by the TCGA Research Network: http://
cancergenome.nih.gov/ and were analyzed using http://
www.cbioportal.org and http://firebrowse.org.
Statistical analysis
Data were expressed as mean ± standard deviation 
(SD). Unless otherwise specified, the significance of 
comparison between two data sets was determined using 
unpaired, two-tailed Student’s t test (GraphPad Prism 
version 5.1) and P < 0.05 defined as significant.
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